Close the license of OncoACP3 from Philochem AG to RayzeBio, Inc
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 31 Jul 2025
- Due
- 30 Sep 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is expected to close in the third quarter of 2025 following the receipt of necessary regulatory approvals and the satisfaction of other customary closing conditions.”
What we found
Evidence strength A What the grades mean
Later 10-Q and 10-K filings state BMS obtained the OncoACP3 license from Philochem in August 2025, before the September 30, 2025 deadline; the exact day is not given.
-
A Bristol Myers Squibb Co. 10-Q filed 2025-10-30
“In August 2025, BMS obtained a global exclusive license from Philochem for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer.” ✓ confirmed on the page
-
A Bristol Myers Squibb Co. 10-Q filed 2025-10-30
“The transaction included an upfront payment of $350 million, which was recorded as Acquired IPRD during the three months ended September 30, 2025.” ✓ confirmed on the page
-
A Bristol Myers Squibb Co. 10-K filed 2026-02-11
“In August 2025, BMS obtained a global exclusive license from Philochem for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer.” ✓ confirmed on the page
Market reaction: the shares moved +8.6% against the S&P 500 over the three sessions around the disclosure (29 Oct 2025 to 3 Nov 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Close
- Deliverable
- OncoACP3 license to RayzeBio
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to necessary regulatory approvals; subject to customary closing conditions
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-BMY-006001 · Corrections policy